AGEN: Agenus Announces Positive Phase 2 Brain Cancer Vaccine Results

Positive Phase 2 Results from Agenus’ Brain Cancer Vaccine Published in Neuro-Oncology

Results Show Improved Survival Against Aggressive Brain Cancer; More Than 90% of Patients Alive After Six Months.  

AGEN's stock surged over 20% this morning on the news

From Business Wire press release:

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. 2 hours ago

Agenus Inc. (AGEN), a biotechnology company developing novel immune system activating treatments for cancers and infectious diseases, today announced results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months. Additionally, the median overall survival was approximately eleven months. This compares favorably to the expected median survival for recurrent Glioblastoma multiforme (GBM) patients of three to nine months1-7. The primary objective of this multi-center, single arm Phase 2 trial was to assess the survival rate at six months.

The data was published in a manuscript in Neuro-Oncology, the official journal of the Society of Neuro-Oncology. GBM is the most common and most aggressive form of primary brain cancer. Despite approved therapy patients with GBM face a poor prognosis. Prophage Series vaccines are currently being studied in both newly diagnosed and recurrent GBM.

From Yahoo!'s Briefing.com newsfeed:

7:01 am Agenus: Positive Phase 2 Results from Agenus' Brain Cancer Vaccine Published in Neuro-Oncology; Results Show Improved Survival Against Aggressive Brain Cancer; More Than 90% of Patients Alive After Six Months (AGEN) : Co announces results published from a Phase 2 study demonstrated that more than 90% of the patients treated with Prophage Series G-200 were alive at six months after surgery and 30% were alive at twelve months. Additionally, the median overall survival was approximately eleven months. This compares favorably to the expected median survival for recurrent Glioblastoma multiforme patients of three to nine months 1-7. The primary objective of this multi-center, single arm Phase 2 trial was to assess the survival rate at six months.

Here is a copy of an October 31, 2013 special email alert where I added significant shares of AGEN to the Explore Portfolio in my newsletter.

Kirk Lindstrom's Investment Letter

Don't Miss Out!

Subscribe Now

Get December Issue for Free!

==>   My returns by year  &  New Record Highs <==

This table shows my newsletter "Core and Explore Portfolios" from 1998 through the end of Q3

End of Day Update for AGEN.  This chart show AGEN tested its Oct/Nov $2.40 low on Friday just before the news today that surged it 31¢.  (Posted 1:55PM PST)